

## Title (en)

HUMAN MONOCLONAL ANTIBODIES TO PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)

## Title (de)

MENSCHLICHE MONOKLONALE ANTIKÖRPER GEGEN PROSTATA-SPEZIFISCHES MEMBRANANTIGEN (PSMA)

## Title (fr)

ANTICORPS MONOCLONAUX HUMAINS DE L'ANTIGENE D'ENVELOPPE PROSTATIQUE SPECIFIQUE (PSMA)

## Publication

**EP 1519747 A4 20060329 (EN)**

## Application

**EP 03721280 A 20030128**

## Priority

- US 0302448 W 20030128
- US 5998902 A 20020128

## Abstract (en)

[origin: WO03064606A2] Isolated human monoclonal antibodies which bind to PSMA, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

## IPC 1-7

**A61K 39/42**; **A61K 39/395**; **C07K 14/00**; **C07K 16/00**

## IPC 8 full level

**A01K 67/027** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61K 47/42** (2006.01); **A61K 47/48** (2006.01); **A61K 51/00** (2006.01); **A61P 13/08** (2006.01); **A61P 13/10** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07K 16/28** (2006.01); **C07K 16/30** (2006.01); **C07K 16/40** (2006.01); **C12N 5/10** (2006.01); **C12N 15/02** (2006.01); **C12N 15/09** (2006.01); **C12P 21/08** (2006.01)

## CPC (source: EP KR)

**A61P 13/08** (2017.12 - EP); **A61P 13/10** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 16/28** (2013.01 - EP KR); **C07K 16/283** (2013.01 - EP); **C07K 16/30** (2013.01 - KR); **C07K 16/3069** (2013.01 - EP); **A61K 2039/505** (2013.01 - EP); **C07K 2317/21** (2013.01 - EP); **C07K 2317/31** (2013.01 - EP); **C07K 2317/54** (2013.01 - EP); **C07K 2317/56** (2013.01 - EP); **C07K 2317/565** (2013.01 - EP); **C07K 2317/732** (2013.01 - EP); **C07K 2317/77** (2013.01 - EP)

## Citation (search report)

- [X] WO 0109192 A1 20010208 - MEDAREX INC [US], et al
- [Y] US 6290956 B1 20010918 - BANDER NEIL H [US]
- [A] WO 0153353 A2 20010726 - NOVARTIS AG [CH], et al
- [A] WO 9429457 A2 19941222 - UNILEVER PLC [GB], et al
- [A] WO 0202641 A1 20020110 - HUMAN GENOME SCIENCES INC [US], et al
- [E] WO 03034903 A2 20030501 - PSMA DEV COMPANY L L C [US], et al
- [T] US 2004175385 A1 20040909 - MARKS JAMES D [US], et al
- [T] WO 2004050850 A2 20040617 - ABGENIX INC [US], et al
- [T] WO 2004020588 A2 20040311 - BIOREXIS PHARMACEUTICAL CORP [US], et al
- [Y] DONOVAN G P ET AL: "ANTIBODY AND VACCINE THERAPIES TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 42, 24 March 2001 (2001-03-24), pages 818, XP001204629, ISSN: 0197-016X
- [Y] HOLMES E H: "PSMA specific antibodies and their diagnostic and therapeutic use", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 10, no. 3, 2001, pages 511 - 519, XP002988381, ISSN: 1354-3784
- [Y] LIU H ET AL: "MONOCLONAL ANTIBODIES TO THE EXTRACELLULAR DOMAIN OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN ALSO REACT WITH TUMOR VASCULAR ENDOTHELIUM", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 17, 1 September 1997 (1997-09-01), pages 3629 - 3634, XP001080132, ISSN: 0008-5472
- See references of WO 03064606A2

## Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

## DOCDB simple family (publication)

**WO 03064606 A2 20030807**; **WO 03064606 A3 20050203**; AU 2003224604 B2 20070614; BR 0307216 A 20051220; CA 2474616 A1 20030807; CN 1652821 A 20050810; EP 1519747 A2 20050406; EP 1519747 A4 20060329; JP 2005518789 A 20050630; KR 20040077889 A 20040907; MX PA04007262 A 20041029; NZ 534687 A 20071026

## DOCDB simple family (application)

**US 0302448 W 20030128**; AU 2003224604 A 20030128; BR 0307216 A 20030128; CA 2474616 A 20030128; CN 03807371 A 20030128; EP 03721280 A 20030128; JP 2003564202 A 20030128; KR 20047011643 A 20030128; MX PA04007262 A 20030128; NZ 53468703 A 20030128